# Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

> **NCT04212065** · PHASE4 · WITHDRAWN · sponsor: **Ohio State University**

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** buprenorphine

## Key facts

- **NCT ID:** NCT04212065
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-21
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212065, "Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04212065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*